Ramona Doyle - 28 Feb 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Medical Officer
Signature: /s/ Nathan Hatfield, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 28 Feb 2022
Net transactions value: +$38,750
Form type: 4
Filing time: 01 Mar 2022, 19:00:24 UTC
Previous filing: 08 Feb 2022
Next filing: 04 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Options Exercise	$38,750	+15,625	+16%	$2.48	112,870	28 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-15,625	-2.3%	$0.000000	678,428	28 Feb 2022	Class A Common Stock	678,428	$2.48	Direct	F1
holding	RXRX	Stock Option (Right to Buy)						76,998	28 Feb 2022	Class A Common Stock	76,998	$11.40	Direct	F2
holding	RXRX	Stock Option (Right to Buy)						4,784	28 Feb 2022	Class A Common Stock	4,784	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Twenty-Five percent (25%) of the 750,000 shares originally subject to the award shall vest one year after December 31, 2020, or the Vesting Commencement Date, and one-forty-eighth (148th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
F2	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.